17:18 , May 11, 2018 |  BC Week In Review  |  Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
12:03 , May 9, 2018 |  BC Extra  |  Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
21:03 , Nov 2, 2017 |  BC Innovations  |  Translation in Brief

A new pocket for D4

The early promise of the dopamine D4 receptor as a therapeutic target for psychiatric disorders hasn’t been borne out because of the difficulty of producing sufficiently selective compounds. Last month in...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
20:14 , May 18, 2017 |  BC Week In Review  |  Company News

Peking University, Boehringer begin research collaboration

Peking University (Beijing, China) and Boehringer Ingelheim GmbH (Ingelheim, Germany) entered into a broad partnership under which they plan to identify targets and develop therapies in cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and...
21:24 , May 16, 2017 |  BC Extra  |  Company News

Peking University, Boehringer begin research collaboration

Peking University and Boehringer Ingelheim GmbH (Ingelheim, Germany) entered into a broad partnership under which they plan to identify targets and develop therapies in cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and CNS diseases....
18:49 , May 12, 2017 |  BC Week In Review  |  Company News

Ex Scientia, Sanofi to design diabetes bispecifics

Artificial intelligence company Ex Scientia Ltd. (Dundee, U.K.) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to design and develop bispecific antibodies to treat metabolic diseases. Ex Scientia declined to disclose specific indications or targets covered by the...
16:14 , May 9, 2017 |  BC Extra  |  Company News

Ex Scientia, Sanofi to design diabetes bispecifics

Artificial intelligence company Ex Scientia Ltd. (Dundee, U.K.) said it partnered with Sanofi (Euronext:SAN; NYSE:SNY) to design and develop bispecific antibodies to treat metabolic diseases. Ex Scientia declined to disclose specific indications or targets covered...